Point of Care Diagnostic test for Molecular Subtyping of Breast Cancer (PoCBreCa Study)

乳腺癌分子分型的护理点诊断试验(PoCBreCa)研究 项目摘要 中低收入国家(LMIC)的乳腺癌发病率正在迅速上升。尽管如此， 人们对这些国家乳腺癌分子亚型的流行病学知之甚少，因为 缺乏免疫组织化学(IHC)的设施、资源和人员，这是目前 乳腺癌的分子亚型。将纳米技术、光子学、 小型化和移动电话网络开发新技术和套件可以克服这些限制 并增加LMIC中乳腺癌分子亚型的可用性。 分子分型的增加将使对决定因素的流行病学研究成为可能 LMIC中乳腺癌分子亚型发病率的长期趋势 产生了相互矛盾的结果。它还将使临床医生能够选择乳腺癌的治疗方法，预测 反应和预后。我们在这个项目中建议开发的试剂盒将产生量化结果 这将为基于定量水平的精准医学打开新的研究和治疗机会 激素受体及其决定因素及其与生殖系和体细胞、遗传学和表观遗传学的关系 变种。 在这个项目中，马里兰大学医学院、巴尔的摩和康奈尔大学的研究人员 在美国，生命伦理和研究中心以及尼日利亚的伊巴丹大学开展工作 共同开发和中试用于乳腺肿瘤分子分型的护理点诊断试剂盒 将其与IHC进行比较，以克服当前的挑战，为乳腺癌开辟新的机遇 研究。

Point of Care Diagnostic test for Molecular Subtyping of Breast Cancer (PoCBreCa) Study Project Summary The incidence of breast cancer in low and middle-income countries (LMIC) is rising rapidly. Despite this, very little is known about the epidemiology of molecular subtypes of breast cancer in these countries because of lack of facilities, resources and personnel for immunohistochemistry (IHC), the current gold standard for molecular subtyping of breast cancer. Innovative strategies that combine nanotechnology, photonics, miniaturization and cell phone networks to develop new technologies and kits can overcome these limitations and increase availability of molecular subtyping of breast cancer in LMIC. Increased availability of molecular subtyping will enable epidemiological research into the determinants and secular trend in the incidence of molecular subtypes of breast cancer in LMIC where previous studies have yielded conflicting results. It will also empower clinicians in their choice of breast cancer treatment, prediction of response and prognosis. The kits that we propose to develop in this project will generate quantitative results which will open new research and treatment opportunities for precision medicine based on quantitative levels of hormone receptors, its determinants and associations with germline and somatic, genetic and epigenetic variations. In this project, researchers at University of Maryland School of Medicine, Baltimore and Cornell University in the United States, and Center for Bioethics and Research, and the University of Ibadan in Nigeria work together to develop and pilot-test a point of care diagnostic kit for molecular subtyping of breast tumors and compare it to IHC in order to overcome current challenges and open new opportunities for breast cancer research.